Successful treatment of aggressive AA amyloidosis with tocilizumab in a patient with polymyalgia rheumatica

dc.contributor.authorAtas, Nuh
dc.contributor.authorCaliskan, Ali Riza
dc.contributor.authorAkatli, Aysenur
dc.date.accessioned2026-04-04T13:33:31Z
dc.date.available2026-04-04T13:33:31Z
dc.date.issued2024
dc.departmentİnönü Üniversitesi
dc.description.abstractPolymyalgia rheumatic (PMR) associated amyloidosis is an extremely rare condition that can be rapidly progressive with high morbidity and mortality and management is challenging. Tocilizumab is a monoclonal anti-IL-6 receptor antibody, which is in the therapeutic arsenal of PMR. The efficiency of tocilizumab in improvement of PMR activity score and decreasing steroid dose is well-established, while efficiency in PMR-associated amyloidosis has not been published. Herein, we reported a PMR patient with amyloid A amyloidosis who was treated effectively with tocilizumab.
dc.identifier.doi10.1093/mrcr/rxae050
dc.identifier.endpage217
dc.identifier.issn2472-5625
dc.identifier.issue1
dc.identifier.orcid0000-0001-5880-4974
dc.identifier.pmid39185604
dc.identifier.scopus2-s2.0-85215549852
dc.identifier.scopusqualityQ3
dc.identifier.startpage214
dc.identifier.urihttps://doi.org/10.1093/mrcr/rxae050
dc.identifier.urihttps://hdl.handle.net/11616/109181
dc.identifier.volume9
dc.identifier.wosWOS:001308839200001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherOxford Univ Press
dc.relation.ispartofModern Rheumatology Case Reports
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectPolymyalgia rheumatica
dc.subjectAA amyloidosis
dc.subjecttocilizumab
dc.subjectIL-6
dc.subjectproteinuria
dc.titleSuccessful treatment of aggressive AA amyloidosis with tocilizumab in a patient with polymyalgia rheumatica
dc.typeArticle

Dosyalar